Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form

Executive Summary

“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.

You may also be interested in...



Shire Course Corrects Lifitegrast And Eyes Ophthalmology Prospects

The specialty pharma has worked with regulators to determine a next step for its late-stage eye drug and intends to build a business unit around the compound.

Financings Of The Fortnight: Recent IPO Slowdown Not Necessarily A Harbinger For A Bad 2014

Series A financing volume is up in recent years, suggesting that 2014 will be a strong year for biotechs opting to go public. Plus financing news from Atara Biotherapeutics, Crescendo Biologics, Acucela and TetraLogic.

Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?

Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054546

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel